-

Charles River Associates (CRA) to Participate in Upcoming Conferences

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that CRA will participate in the following investor conferences:

UBS Global Technology and AI Conference
Date: Monday, December 1, 2025
Presentation: 12:15 p.m. MST (2:15 p.m. EST)

Noble Capital Markets Annual Emerging Growth Equity Conference
Date: Wednesday, December 3
Presentation: 9:30 a.m. EST

Sidoti Year-End Virtual Investor Conference
Date: Wednesday, December 10
Presentation: 10:45 a.m. EST

Live webcasts of the UBS and Sidoti presentations will be available on the Company’s investor relations website. Archived replays will be available shortly after each presentation. CRA President and Chief Executive Officer Paul Maleh, Chief Financial Officer Eric Nierenberg, and Chief Corporate Development Officer Chad Holmes will be available for meetings with investors at these conferences.

About Charles River Associates (CRA)
Charles River Associates® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Instagram, and Facebook.

Contacts

Chad Holmes
Charles River Associates
investor@crai.com
312-377-2322

Nicholas Manganaro
Sharon Merrill Advisors
crai@investorrelations.com
617-542-5300

Charles River Associates

NASDAQ:CRAI

Release Versions

Contacts

Chad Holmes
Charles River Associates
investor@crai.com
312-377-2322

Nicholas Manganaro
Sharon Merrill Advisors
crai@investorrelations.com
617-542-5300

More News From Charles River Associates

Charles River Associates (CRA) Bolsters Life Sciences Practice with Appointment of Christopher Zealey as Vice President

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced the appointment of Christopher Zealey as a Vice President in the firm’s Life Sciences Practice. “I am pleased to welcome Chris to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “His areas of expertise include cross functional and medical strategic and tactical planning, insight genera...

Charles River Associates (CRA) Adds Harvard Business School Professor as Academic Affiliate to Antitrust & Competition Economics Practice

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced the addition of Professor Feng Zhu as an Academic Affiliate in the firm’s Antitrust & Competition Economics Practice. “I am pleased to welcome Feng to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He is a recognized expert on digital transformation, competitive strategy, and bus...

Charles River Associates (CRA) Names Patrick Hillan Vice President, Expanding Life Sciences Commercial Strategy Expertise

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced the addition of Patrick Hillan as a Vice President in the firm’s Life Sciences Practice. “I am happy to welcome Patrick to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He has deep expertise in medical affairs strategy, having partnered with global pharmaceutical and biotechnology c...
Back to Newsroom